Dear Editor

Article

In answer to the question: "What specifically makes SLT different from ALT in its action?" we offer the following response:

Dear Dr Bastawrous,
In answer to the question: "What specifically makes SLT different from ALT in its action?" we offer the following response:

The mechanical theory of IOP reduction in argon laser trabeculoplasty (ALT) proposes that a thermal burn contracts tissue and stretches open those adjacent, untreated regions of the trabecular meshwork (TM) to increase outflow. However, in SLT, disruption or death of pigmented TM cells alone appears to induce a response that results in IOP reduction.

Previous clinical trials comparing ALT to SLT showed SLT to have equal or more favourable outcomes. However, SLT was better tolerated and produced less discomfort compared with ALT.

Suggested reading: M.A. Latina & J.M. deLeon. Selective Laser Trabeculoplasty. Ophthalmol. Clin. N. Am. 2005;409-419.

Arusha Gupta
SUNY Stony Brook School of Medicine, Stony Brook, New York, USA

Lawrence F. Jindra, MD
Columbia University, New York, USA

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.